- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 24, 2022
Distillery Therapeutics
An EpCAM- and CD133-expressing cell population for biliary disease
BioCentury | May 30, 2020
Translation in Brief
Empirica’s glioblastoma CAR T therapy in mice; plus tumor microbiomes by tumor type, Senhwa and more
BioCentury’s roundup of preclinical news
BioCentury | Jan 10, 2020
Emerging Company Profile
Empirica: Building a new model for brain cancer
Empirica is developing antibody therapeutics based on the biology of recurrence
BioCentury | May 4, 2018
Targets & Mechanisms
Solid hopes for T cell bispecifics
Will next-generation T cell bispecifics find their place in solid tumors?
BioCentury | May 5, 2016
Distillery Therapeutics
Therapeutics: GD3 ganglioside; ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase 1 (ST8SIA1); prominin 1 (PROM1; CD133)
BioCentury | May 19, 2014
Emerging Company Profile
Curtana: Curtains for CSCs
Curtana's OLIG2 inhibitors sensitize brain cancer by targeting stem cells
Items per page:
1 - 10 of 29